Literature DB >> 3486819

Direct induction of human B-cell differentiation by recombinant interleukin-2.

S Romagnani, G Del Prete, M G Giudizi, R Biagiotti, F Almerigogna, A Tiri, A Alessi, M Mazzetti, M Ricci.   

Abstract

Recombinant interleukin-2 (rIL-2) induced highly purified human tonsillar B cells to differentiate into immunoglobulin (Ig)-producing cells in vitro. The B-cell response was not due to rIL-2-contaminating substances, but reflected the activity of IL-2 itself, since it was inhibited by addition to the cultures of anti-TAC monoclonal antibody. The rIL-2-induced B-cell response was apparently not mediated by factors released by residual T cells present in B-cell suspensions at undetectable levels, since supernatants (SN) from unstimulated autologous T cells cultured at concentrations even much higher than those possibly contaminating B-cell suspensions did not induce any detectable Ig production. In addition, the Ig production by B cells cultured with SN prepared from high numbers of autologous T cells stimulated with rIL-2, as well as from allo-activated or mitogen-stimulated T cells, was of the same magnitude as the Ig production resulting from direct addition of rIL-2 concentrations comparable with those present in the supernatants. After centrifugation on Percoll density gradients, most of the tonsillar B cells responsive to rIL-2 were recovered in the lower density cell fraction containing a number of larger activated B cells. Moreover, B-cell enriched suspensions from peripheral blood (PB) (which usually contains a lower number of in vivo activated B cells than tonsil) showed poor or no response to rIL-2 alone, but displayed significant Ig production when rIL-2 was added to the cultures in the presence of Staphylococcus aureus Cowan I (SAC) bacteria.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486819      PMCID: PMC1452648     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Effect of recombinant IL 2 and gamma-IFN on proliferation and differentiation of human B cells.

Authors:  T Nakagawa; T Hirano; N Nakagawa; K Yoshizaki; T Kishimoto
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

2.  Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease.

Authors:  S Romagnani; G F Del Prete; E Maggi; G Bellesi; G Biti; P L Rossi Ferrini; M Ricci
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

3.  Demonstration of the involvement of interleukin 2 in the differentiation of Staphylococcus aureus Cowan I-stimulated B cells.

Authors:  T Teranishi; T Hirano; B H Lin; K Onoue
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

4.  Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells.

Authors:  M C Mingari; F Gerosa; G Carra; R S Accolla; A Moretta; R H Zubler; T A Waldmann; L Moretta
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

5.  Human helper T cell factor(s). III. Characterization of B cell differentiation factor I (BCDF I).

Authors:  T Hirano; T Teranishi; K Onoue
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

6.  Frequent coexpression of cytolytic activity and lymphokine production among human T lymphocytes. Production of B cell growth factor and interleukin 2 by T8+ and T4+ cytolytic clones.

Authors:  M C Mingari; A Moretta; E Maggi; G Pantaleo; F Gerosa; S Romagnani; L Moretta
Journal:  Eur J Immunol       Date:  1984-11       Impact factor: 5.532

7.  Use of monoclonal antibodies for the characterization of novel DNA-binding proteins recognized by human autoimmune sera.

Authors:  W H Reeves
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

8.  Expression of Tac antigen on activated normal human B cells.

Authors:  M Tsudo; T Uchiyama; H Uchino
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

9.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  Activated B cells express receptors for, and proliferate in response to, pure interleukin 2.

Authors:  R H Zubler; J W Lowenthal; F Erard; N Hashimoto; R Devos; H R MacDonald
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

View more
  6 in total

1.  Role of interleukin-2 and interferon-gamma in inducing production of IgG subclasses in lymphocytes of human newborns.

Authors:  Y Kawano; T Noma
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

2.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

3.  The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors.

Authors:  T Commes; B Klein; M Jourdan; G Clofent; F Houssiau; J Grenier; R Bataille
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

4.  Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation.

Authors:  T Tanaka; O Saiki; S Doi; M Suemura; S Negoro; S Kishimoto
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

5.  Expression of functional interleukin 2 receptors on chronic lymphocytic leukaemia B lymphocytes is modulated by recombinant interleukin 2.

Authors:  J J Murphy; V Malkovska; L Hudson; R E Millard
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

6.  Interleukin 2-regulated in vitro antibody production following a single spinal manipulative treatment in normal subjects.

Authors:  Julita A Teodorczyk-Injeyan; Marion McGregor; Richard Ruegg; H Stephen Injeyan
Journal:  Chiropr Osteopat       Date:  2010-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.